Stocks · Health care · Pharmaceutical Preparations

Acrivon Therapeutics, Inc.

ACRV Clue Score43

United States Fiscal year ends December CIK 0001781174 Results filed 12 Aug 2026

Add to watchlist

What the insiders did Net buying

Individual transactions

Insider

Date

Role

Action

Price

Amount

Adam D. Levy

14 Jan 2026

Chief Financial Officer

Buy

8,832

$1.70

$15.00K

Peter Blume-Jensen

14 Jan 2026

President and CEO

Buy

49,000

$1.68

$82.12K

Eric Devroe

13 Jan 2026

Chief Operating Officer

Buy

10,000

$1.72

$17.22K

Perceptive Advisors LLC

11 Apr 2024

10% owner

Buy indirect

2,353,000

$8.50

$20.00M

Ra Capital Management, L.p.

17 Nov 2022

Director

Buy indirect

3,389,500

$12.50

$42.37M

Chione Ltd

17 Nov 2022

10% owner

Buy

400,000

$12.50

$5.00M

Show all 31 transactions →

What was left out

Form 4 filings counted 184

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 37

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 21

Transactions with no price 0

Shares from compensation/vesting 18,397,067

History held since 16 Nov 2022